Evidence map›Paper›PMID 37225048›Full record

ArticleExperimental hematology2023

Comparative analysis of Tet2 catalytic-deficient and knockout bone marrow over time.

Julio C Flores, Kyoko Ito, Cheng-Yen Huang, Qin Tang, Chie Yanase, Keisuke Ito, Meelad M Dawlaty

Open access · hybridAbstract read
In one paragraph

Article in Experimental hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Julio C FloresRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Genetics, Albert Einstein College of Medicine, Bronx, NY; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
Kyoko ItoRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY; Departments of Oncology and Medicine, Albert Einstein College of Medicine-Montefiore Health System, Bronx, NY; Montefiore Einstein Cancer Center, Bronx, NY.
Cheng-Yen HuangRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Genetics, Albert Einstein College of Medicine, Bronx, NY; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
Qin TangRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Genetics, Albert Einstein College of Medicine, Bronx, NY; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
Chie YanaseRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY.
Keisuke ItoRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY; Departments of Oncology and Medicine, Albert Einstein College of Medicine-Montefiore Health System, Bronx, NY; Montefiore Einstein Cancer Center, Bronx, NY. Electronic address: keisuke.ito@einsteinmed.edu.
Meelad M DawlatyRuth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Genetics, Albert Einstein College of Medicine, Bronx, NY; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY; Montefiore Einstein Cancer Center, Bronx, NY. Electronic address: meelad.dawlaty@einsteinmed.edu.
Albert Einstein College of Medicine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
In Vivo Sickle Cell Vasoocclusion: Adhesion MechanismsR01HL069438 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI KELLY, LIBUSHA · 2001 to 2024
$9.5M
The Roles of Lipid Metabolism in the Maintenance of Hematopoietic Stem CellsR01DK098263 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Keisuke Ito · 2013 to 2026
$5.2M
Dissecting the canonical and non-canonical functions of Tet2 in hematopoietic stem cells and hematologic disordersR01HL148852 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Meelad Dawlaty, Keisuke Ito · 2019 to 2026
$4.4M
Single cell approach to uncovering factors regulating HSC division symmetry in vivoR01DK115577 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ITO, KEISUKE, LIN, CHARLES P. · 2017 to 2021
$2.9M
Role of Tet proteins in epigenetic regulation of embryonic stem cell biologyR01GM122839 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DAWLATY, MEELAD · 2018 to 2022
$1.8M
Epigenetic regulation of stem cells and development by the DNA dioxygenase Tet2F31GM140554 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI FLORES, JULIO C · 2021 to 2023
$155k
NCI NIH HHS P30 CA013330NHLBI NIH HHS R01 HL069438NHLBI NIH HHS R01 HL148852NIDDK NIH HHS R01 DK098263NIDDK NIH HHS R01 DK115577NIGMS NIH HHS F31 GM140554NIGMS NIH HHS R01 GM122839
6 · The paper itself

Abstract

TET2 is a member of the Ten-eleven translocation (Tet) family of DNA dioxygenases that regulate gene expression by promoting DNA demethylation (enzymatic activity) and partnering with chromatin regulatory complexes (nonenzymatic functions). TET2 is highly expressed in the hematopoietic lineage, where its molecular functions are the subject of continuous investigations because of the prevalence of TET2 mutations in hematologic malignancies. Previously, we have implicated Tet2 catalytic and noncatalytic functions in the regulation of myeloid and lymphoid lineages, respectively. However, the impact of these functions of Tet2 on hematopoiesis as the bone marrow ages remains unclear. Here, we conducted comparative transplantations and transcriptomic analyses of 3-, 6-, 9-, and 12-month-old Tet2 catalytic mutant (Mut) and knockout (KO) bone marrow. Tet2 Mut bone marrow of all ages exclusively caused hematopoietic disorders of the myeloid lineage. In contrast, young Tet2 KO bone marrow developed both lymphoid and myeloid diseases, whereas older Tet2 KO bone marrow predominantly elicited myeloid disorders with shorter latency than age-matched Tet2 Mut bone marrow. We identified robust gene dysregulation in Tet2 KO Lin

Indexed as

DioxygenasesHematologic DiseasesHematologic NeoplasmsMyelodysplastic SyndromesBone MarrowHematopoiesisHumansInfantMutationDioxygenases

Identifiers

PMID37225048
PMCPMC10524687
OpenAlexW4377287123

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.